Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Community Oncologist's View: Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approval


Who's the expert?

Name: Dr Salim Contractor

Institution: NY Oncology Hematology

  • Medical oncologist within community practice (NY Oncology Hematology).
  • Currently manages 20 patients with AML, 15 stage 4 RCC and 10 stage 1-3 RCC patients.
  •  Board Certified in Internal Medicine and Medical Oncology; fellowship trained (Oncology) at Mount Sinai.

Interview Questions

Please describe your clinical practice; roughly how many patients with AML do you currently manage?

Added By: c_admin

Have you prescribed Jazz Pharma's Vyxeos and/or Agios’ Idhifa/Tibsovo?

Added By: c_admin

What are your thoughts on the FLT3 inhibitors (midostaurin and gilteritinib)? When do you test for FLT3 mutations and where do you see them best fitting into the treatment plan (maintenance? relapse?).

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.